Quote | Medexus Pharmaceuticals Inc (OTCMKTS:MEDXF)
Last: | $1.645 |
---|---|
Change Percent: | -9.42% |
Open: | $1.51 |
Close: | $1.645 |
High: | $1.69 |
Low: | $1.51 |
Volume: | 47,935 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Medexus Pharmaceuticals Inc (OTCMKTS:MEDXF)
2024-06-26 10:28:06 ET Medexus Pharmaceuticals Inc. (MEDXF) Q4 2024 Earnings Conference Call June 26, 2024 08:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Kenneth d'Entremont - CEO Marcel Konrad - CFO Conference Call Participants...
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Message Board Posts | Medexus Pharmaceuticals Inc (OTCMKTS:MEDXF)
Subject | By | Source | When |
---|---|---|---|
Any thoughts on the quarter? | rado | investorshub | 08/17/2021 8:55:33 PM |
Wow! A post?? Yeah, amazing potential. Going much higher | ronpopeil | investorshub | 06/12/2021 12:11:50 AM |
Let's gooooo $MEDXF | Phils Goodman | investorshub | 06/11/2021 11:47:30 PM |
I like this one a lot. Strong revenues. | ronpopeil | investorshub | 04/22/2021 8:29:43 PM |
started a new position last week and up | arnoldisking | investorshub | 03/16/2021 9:40:12 PM |
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc Company Name:
MEDXF Stock Symbol:
OTCMKTS Market:
Medexus Pharmaceuticals Inc Website:
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended Mar...
2024-06-06 12:08:44 ET In the United States, a new drug application, or NDA, is the vehicle through which drug sponsors formally propose that the FDA approve a new %Pharmaceutical for sale and marketing. And news that the FDA has accepted this firm’s resubmission is sending share...